• Active, not recruiting

NCT01864018: Phase 1/2: Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in NDMM or L C Amyloid

Updated: Apr 25

NCT01864018: Phase 1/2: Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis


ixazomib

Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis


Sponsor:

Mayo Clinic


Collaborator:

National Cancer Institute (NCI)


Principal Investigator:

Shaji Kumar Mayo Clinic


This phase I/II trial studies the side effects and the best dose of cyclophosphamide when given together with ixazomib citrate and dexamethasone in treating patients with previously untreated symptomatic multiple myeloma or light chain amyloidosis. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cyclophosphamide together with ixazomib citrate and dexamethasone may be a better treatment for multiple myeloma or light chain amyloidosis.


Locations

Mayo Clinic in Arizona

Mayo Clinic Rochester, Minnesota


ClinicalTrials.gov Identifier: NCT01864018

Official Title: Phase 1/2 Trial of Ixazomib in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

First Posted : May 29, 2013


https://clinicaltrials.gov/ct2/show/NCT01864018

 

Ixazomib: National Cancer Institute

Ixazomib: MedlinePlus Drug Information


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information


Cyclophosphamide: National Cancer Institute

Cyclophosphamide: MedlinePlus Drug Information

 

Drug: Cyclophosphamide

Drug: Dexamethasone

Drug: Ixazomib Citrate

Other: Laboratory Biomarker Analysis

Other: Pharmacological Study

Other: Quality-of-Life Assessment

Other: Questionnaire Administration

 

Locations

Mayo Clinic in Arizona

Mayo Clinic Rochester, Minnesota

 

Blood Cancer J;2018

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma

https://pubmed.ncbi.nlm.nih.gov/30061664/










Posts Archive